Table 4.
Summary of trials of CD19 CAR-T therapy with B-cell non-Hodgkin lymphoma.
| Schuster et al. (81) | Kochenderfer et al. (82) | Schuster et al. (83) | Locke et al. (84) | Abramson et al. (85) | Wang et al. (45) | Jacobson et al. (43) | |
|---|---|---|---|---|---|---|---|
| Patients, n | 28 | 22 | 111 | 108 | 268 | 74 | 87 |
| Disease(s) | DLBCL, FL | DLBCL, tFL, PMBL, MCL, FL | DLBCL | DLBCL, tFL, PMBL | DLBCL, PMBL, FL3B | MCL | FL, MZL |
| Co-stimulatory domain | 4-1BB/CD3ζ | CD28/CD3ζ | 4-1BB/CD3ζ | CD28/CD3ζ | 4-1BB/CD3ζ | CD28/CD3ζ | CD28/CD3ζ |
| Median follow-up, mo | 28.6 | 12.5 | 14 | 27.1 | 10.8 | 13.1 | 11.5 |
| Prior allo-HCT, % | 7 | 0 | 0 | 0 | 3 | 0 | NA |
| CR/PR, % | 57/7 | 55/18 | 40/12 | 58/25 | 53/20 | 59/36 | 80/15 |
| Allo-HCT post-CR,% | 11 | 4 | 0 (6 non-responders underwent allo-HCT) | 5 | NA | 1.3 | NA |
| OS | DLBCL: 50% at 22 mo FL: 93% at 28.6 mo |
NA | 59% at 12 mo | 50.5% at 24 mo | mOS 10.8 mo | 83% at 12 mo | NA |
| PFS in CR/PR, % | DLBCL: 43/0 at 28.6 mo FL: 70/0 at 28.6 mo |
63/0 at 12 mo | 83% at 12 mo | 75/72 at 24 mo | mDoR 13.3 mo; mPFS 6.8 mo |
61% at 12 mo (all patients) | NA |
Allo-HCT, allogeneic hematopoietic cell transplantation; CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NA, not available; OS, overall survival; PFS, progression-free survival; PMBL, primary mediastinal B-cell lymphoma; PR, partial response; tFL, transformed FL.